Alzheimer's Disease Behavioral and psychological symptoms of dementia
Conditions
Interventions
Tachikawa electrolyzed calcium given on twice daily for 24 weeks followed, until disease progression or unmanageable toxicity
Sponsors
Homma Sadamu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) At least one Neuropsychiatric Inventory-Questionnaire score more than 2 2) Probable Alzheimer's Disease dementia in the criteria by National Institute of Neurological and Communicative Disorders and Stroke AD and Related Disorders Association 3) Compatible with 2) during the observation one month prior to the start of the drug administration 4) Over 60 years old 5) Male and Female (Both) 6) Agreement by the legal representative 7) Certain performance of the treatment and observation based on the study schedule 8) No matter about the intake of other calcium drug types 9) Normal or low serum calcium level, and in case of hypoalbuminemia, calculate and judge corrected calcium level.
Exclusion criteria
Exclusion criteria: 1) Severe damage of hepatic, renal, and cardiovascular function (According to CTCAE version 5.0, Grade 3) 2) Malignant neoplasms 3) History of severe drug allergy such as anaphylaxic reaction or severe drug side effects 4) Intake of the unapproved anti-dementia drug for the medical test within 12 weeks prior to the agreement with this study 5) Pregnancy certain or possible 6) Breastfeed 7) Inadequate to enroll in this study judged by the chief or co-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropsychiatric InventryInventory-Questionnaire | — |
Secondary
| Measure | Time frame |
|---|---|
| Dementia Behavior Disturbance Scale | — |
Contacts
Public ContactSadamu Homma
Soujinkai Hospital
Outcome results
None listed